PT - JOURNAL ARTICLE AU - Lynall, Mary-Ellen AU - Soskic, Blagoje AU - Hayhurst, James AU - Schwartzentruber, Jeremy AU - Levey, Daniel F. AU - Pathak, Gita A. AU - Polimanti, Renato AU - Gelernter, Joel AU - Stein, Murray B. AU - Trynka, Gosia AU - Clatworthy, Menna R. AU - Bullmore, Ed TI - Genetic variants associated with cross-disorder and disorder-specific risk for psychiatric disorders are enriched at epigenetically active sites in peripheral lymphoid cells AID - 10.1101/2021.08.04.21261606 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.04.21261606 4099 - http://medrxiv.org/content/early/2021/08/08/2021.08.04.21261606.short 4100 - http://medrxiv.org/content/early/2021/08/08/2021.08.04.21261606.full AB - Multiple psychiatric disorders have been associated with abnormalities in both the innate and adaptive immune systems. The role of these abnormalities in pathogenesis, and whether they are driven by psychiatric risk variants, remains unclear. We tested for enrichment of GWAS variants associated with multiple psychiatric disorders (cross-disorder or trans-diagnostic risk), or 5 specific disorders (cis-diagnostic risk), in regulatory elements in immune cells. We used three independent epigenetic datasets representing multiple organ systems and immune cell subsets. Trans-diagnostic and cis-diagnostic risk variants (for schizophrenia and depression) were enriched at epigenetically active sites in brain tissues and in lymphoid cells (T, B and NK cells), especially stimulated CD4+ T cells. There was no evidence for enrichment of either trans-risk or cis-risk variants for schizophrenia or depression in myeloid cells. This suggests a model where stimuli (e.g. infection) activate T cells to unmask the effects of psychiatric risk variants, contributing to the pathogenesis of mental health disorders.Competing Interest StatementE.T.B. serves as a member of the scientific advisory board of Sosei Heptares and as a consultant for GlaxoSmithKline. J.G. and R.P. are paid for their editorial work for Complex Psychiatry journal. M.B.S. in the past 3 years has received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, Boehringer Ingelheim, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, Engrail Therapeutics, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech. M.B.S. has stock options in Oxeia Biopharmaceuticals and EpiVario. He is paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry). He has also received research support from NIH, Department of Veterans Affairs, and the Department of Defense. He is on the scientific advisory board for the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America.Funding StatementM.E.L is supported by the Medical Research Council. This work was additionally supported by the NIHR Cambridge Biomedical Research Centre. E.T.B. is supported by an NIHR Senior Investigator award. B.S. is funded by the Open Targets grant OTAR040. G.T. is supported by the Open Targets and the Wellcome Trust (grant WT206194). DFL is supported by a US Veterans Affairs Career Development Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A - Reanalysis of publicly available datasetsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll datasets and code used for this analysis are publicly (see Supplementary Table 2 for full details) Github repository: https://github.com/maryellenlynall/psychimmgen2021 Processed datasets deposited in Zenodo: https://doi.org/10.5281/zenodo.5153661 https://github.com/maryellenlynall/psychimmgen2021 https://doi.org/10.5281/zenodo.5153661